These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 34817584)

  • 1. Assessment of Frailty and Association With Progression of Benign Prostatic Hyperplasia Symptoms and Serious Adverse Events Among Men Using Drug Therapy.
    Bauer SR; Walter LC; Ensrud KE; Suskind AM; Newman JC; Ricke WA; Liu TT; McVary KT; Covinsky K
    JAMA Netw Open; 2021 Nov; 4(11):e2134427. PubMed ID: 34817584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater.
    Kaplan SA; McConnell JD; Roehrborn CG; Meehan AG; Lee MW; Noble WR; Kusek JW; Nyberg LM;
    J Urol; 2006 Jan; 175(1):217-20; discussion 220-1. PubMed ID: 16406915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy.
    Fwu CW; Eggers PW; Kirkali Z; McVary KT; Burrows PK; Kusek JW
    J Urol; 2014 Jun; 191(6):1828-34. PubMed ID: 24342143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monotherapy versus combination drug therapy for the treatment of benign prostatic hyperplasia.
    Logan YT; Belgeri MT
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):103-14. PubMed ID: 16129387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
    Hwang EC; Gandhi S; Jung JH; Imamura M; Kim MH; Pang R; Dahm P
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007360. PubMed ID: 30306544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis.
    Gacci M; Ficarra V; Sebastianelli A; Corona G; Serni S; Shariat SF; Maggi M; Zattoni F; Carini M; Novara G
    J Sex Med; 2014 Jun; 11(6):1554-66. PubMed ID: 24708055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrasound image features of intravesical prostatic protrusion indicated failure of medication therapy of finasteride and doxazosin in patients with benign prostatic hyperplasia (LUTS/BPH).
    Liu Q; Zhu Y; Liu J; Qi J; Kang J
    Int Urol Nephrol; 2017 Mar; 49(3):399-404. PubMed ID: 27987130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin.
    Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Karashchuk E; Prokofyeva A; Loparev S
    J Sex Med; 2018 Nov; 15(11):1579-1590. PubMed ID: 30415813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with omega-3 fatty acids plus tamsulocin and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH).
    Ghadian A; Rezaei M
    Inflammopharmacology; 2017 Aug; 25(4):451-458. PubMed ID: 28391389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
    Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
    Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of a Fixed-Dose Combination Therapy of Tamsulosin and Tadalafil for Patients With Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Randomized, Double-Blinded, Active-Controlled Trial.
    Kim SW; Park NC; Lee SW; Yang DY; Park JK; Moon DG; Yang SK; Lee SW; Moon KH; Ahn TY; Kim SW; Park K; Min KS; Ryu JK; Son H; Jung J; Hyun JS
    J Sex Med; 2017 Aug; 14(8):1018-1027. PubMed ID: 28760246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia.
    Fwu CW; Eggers PW; Kaplan SA; Kirkali Z; Lee JY; Kusek JW
    J Urol; 2013 Jul; 190(1):187-93. PubMed ID: 23357210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
    McConnell JD; Roehrborn CG; Bautista OM; Andriole GL; Dixon CM; Kusek JW; Lepor H; McVary KT; Nyberg LM; Clarke HS; Crawford ED; Diokno A; Foley JP; Foster HE; Jacobs SC; Kaplan SA; Kreder KJ; Lieber MM; Lucia MS; Miller GJ; Menon M; Milam DF; Ramsdell JW; Schenkman NS; Slawin KM; Smith JA;
    N Engl J Med; 2003 Dec; 349(25):2387-98. PubMed ID: 14681504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia?
    McVary KT; Rogers T; Mahon J; Gupta NK
    J Sex Med; 2018 Dec; 15(12):1728-1738. PubMed ID: 30446471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group.
    Lepor H; Williford WO; Barry MJ; Haakenson C; Jones K
    J Urol; 1998 Oct; 160(4):1358-67. PubMed ID: 9751354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Periprostatic fat thickness measured on MRI correlates with lower urinary tract symptoms, erectile function, and benign prostatic hyperplasia progression.
    Zhang B; Chen X; Liu YH; Gan Y; Liu PH; Chen Z; Xia WP; Dai GY; Ru F; Jiang ZX; He Y
    Asian J Androl; 2021; 23(1):80-84. PubMed ID: 32859870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction.
    Pang R; Zhou XY; Wang X; Wang B; Yin XL; Bo H; Jung JH
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD012336. PubMed ID: 33567116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Associations between Concurrent Changes in Phenotypic Frailty and Lower Urinary Tract Symptoms among Older Men.
    Bauer SR; McCulloch CE; Cawthon PM; Ensrud KE; Suskind AM; Newman JC; Harrison SL; Senders A; Covinsky K; Marshall LM
    J Frailty Aging; 2023; 12(2):117-125. PubMed ID: 36946708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
    Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.